Naegeli Hanspeter, Bresson Jean-Louis, Dalmay Tamas, Dewhurst Ian Crawford, Epstein Michelle M, Firbank Leslie George, Guerche Philippe, Hejatko Jan, Moreno Francisco Javier, Nogue Fabien, Rostoks Nils, Sanchez Serrano Jose Juan, Savoini Giovanni, Veromann Eve, Veronesi Fabio, Casacuberta Josep, De Schrijver Adinda, Messean Antoine, Patron Nicola, Zurbriggen Matias, Alvarez Fernando, Devos Yann, Gennaro Andrea, Streissl Franz, Papadopoulou Nikoletta, Mullins Ewen
EFSA J. 2021 Feb 5;19(2):e06301. doi: 10.2903/j.efsa.2021.6301. eCollection 2021 Feb.
Synthetic Biology (SynBio) is an interdisciplinary field at the interface of engineering and biology aiming to develop new biological systems and impart new functions to living cells. EFSA has been asked by the European Commission to evaluate SynBio developments in agri-food with the aim of identifying the adequacy of existing guidelines for risk assessment and determine if updated guidance is needed. The scope of this opinion covers the molecular characterisation and environmental risk assessment of such genetically modified plants obtained through SynBio, meant to be for cultivation or food and feed purposes. The previous work on SynBio by the non-food scientific Committees (2014, 2015) was used and complemented with the output of a horizon scanning exercise, which was commissioned by the EFSA to identify the most realistic and forthcoming SynBio cases of relevance to this remit. The horizon scan did not identify other sectors/advances in addition to the six SynBio categories previously identified by the non-food scientific committees of the European Commission. The exercise did show that plant SynBio products reaching the market in the near future (next decade) are likely to apply SynBio approaches to their development using existing genetic modification and genome editing technologies. In addition, three hypothetical SynBio case studies were selected by the working group of the Panel on Genetically Modified Organisms (GMO), to further support the scoping exercise of this Scientific Opinion. Using the selected cases, the GMO Panel concludes that the requirements of the EU regulatory framework and existing EFSA guidelines are adequate for the risk assessment of SynBio products to be developed in the next 10 years, although specific requirements may not apply to all products. The GMO Panel acknowledges that as SynBio developments evolve, a need may exist to adjust the guidelines to ensure they are adequate and sufficient.
合成生物学是工程学与生物学交叉的跨学科领域,旨在开发新的生物系统并赋予活细胞新功能。欧盟委员会要求欧洲食品安全局(EFSA)评估合成生物学在农业食品领域的发展,以便确定现有风险评估指南是否充分,并判断是否需要更新指南。本意见的范围涵盖通过合成生物学获得的此类转基因植物的分子特征及环境风险评估,这些植物旨在用于种植或作为食品及饲料。非食品科学委员会此前关于合成生物学的工作(2014年、2015年)被采用,并辅以一次前沿扫描活动的成果,该活动由欧洲食品安全局委托开展,以确定与本任务相关的最现实且即将出现的合成生物学案例。前沿扫描未发现除欧盟委员会非食品科学委员会先前确定的六个合成生物学类别之外的其他领域/进展。该活动确实表明,在不久的将来(未来十年)进入市场的植物合成生物学产品可能会利用现有的基因改造和基因组编辑技术,采用合成生物学方法进行研发。此外,转基因生物小组的工作组挑选了三个假设的合成生物学案例研究,以进一步支持本科学意见的范围界定工作。利用所选案例,转基因生物小组得出结论,欧盟监管框架和欧洲食品安全局现有指南的要求对于未来十年拟开发的合成生物学产品的风险评估是足够的,尽管具体要求可能并非适用于所有产品。转基因生物小组承认,随着合成生物学的发展,可能需要调整指南以确保其充分性和适用性。